Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 14Leukemia, Myeloid, Acute 7Neoplasms 3Neoplasm Metastasis 3Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neuroblastoma 2Liver Neoplasms 2Hepatoblastoma 2Fibrolamellar hepatocellular carcinoma 2Tongue Neoplasms 1Thyroid cancer, Hurthle cell 1Thyroid Diseases 1Sarcoma, Myeloid 1Salivary Gland Neoplasms 1Rhabdomyosarcoma 1Recurrence 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors 1Melanoma 1Gastrointestinal Stromal Tumors 1Desmoplastic Small Round Cell Tumor 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Imatinib Mesylate 12Sunitinib 10ripretinib 5regorafenib 4Blood Specimen Collection 3envafolimab 2Specimen Handling 2Paclitaxel 2Magnetic Resonance Spectroscopy 2IDRX-42 2Biopsy 2trastuzumab deruxtecan 1spartalizumab 1ribociclib 1pemigatinib 1palbociclib 1olverembatinib 1nilotinib 1guadecitabine 1binimetinib 1avelumab 1avapritinib 1atezolizumab 1apatinib 1Temozolomide 1TAS-116 1Surgical Instruments 1Sorafenib 1Rogaratinib 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Stromal Tumors × Sorafenib × 1 year × Clear all
NCT00265798 2026-04-28

Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate

National Cancer Institute (NCI)

Phase 2 Active not recruiting
38 enrolled 9 charts
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡